Comparative Pharmacology
Head-to-head clinical analysis: FOAMCOAT versus POLYSPORIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOAMCOAT versus POLYSPORIN.
FOAMCOAT vs POLYSPORIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOAMCOAT is a proprietary fibrin sealant containing human fibrinogen and thrombin. When applied topically, thrombin converts fibrinogen into fibrin monomers that polymerize into a stable clot. This forms a mechanical barrier and promotes hemostasis through the final step of the coagulation cascade.
Polysporin is a combination of polymyxin B and bacitracin. Polymyxin B disrupts bacterial cell membrane by binding to lipopolysaccharides, increasing permeability. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan synthesis.
FOAMCOAT is a topical hemostatic agent; standard adult dose is 1 to 2 mL applied directly to bleeding site, repeated as needed.
Apply a thin layer topically to the affected area 1 to 3 times daily. If using the ointment, cover with a sterile bandage if desired.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Polymyxin B: 6–7 hours (impaired renal function: prolonged). Bacitracin: 1.5 hours (topical; not systemically absorbed).
Primarily renal excretion of intact drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Polysporin (polymyxin B/bacitracin) ophthalmic/otic/topical: Minimal systemic absorption. Renal elimination for absorbed fraction: <1% of dose.
Category C
Category C
Topical Antibiotic
Topical Antibiotic